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Endothelial functionTo assess the role of angiopoietin (Ang)-1 and Ang-2 and to investigate the clinical significance of serum
levels of them in systemic juvenile idiopathic arthritis (s-JIA)-associated macrophage activation syn-
drome (MAS), we determined these levels in 51 patients with s-JIA, 11 patients with polyarticular JIA
(poly-JIA), 12 patients with virus associated hemophagocytic syndrome (VAHS), 12 patients with
Kawasaki disease (KD), and 15 age-matched healthy controls (HC). The results were compared with clin-
ical features of MAS. During the MAS phase, serum Ang-1 levels were significantly decreased compared
with those during the active and inactive phases. Serum Ang-2/1 ratio were significantly elevated during
the MAS phase, compared with those during the active and inactive phases. There was a rapid increase in
the Ang-2/1 ratio at the onset of MAS. Serum Ang-1 and the Ang-2/1 ratio significantly correlated with
measures of disease activity, including AST and LDH. Ang-2/1 dysregulation was also observed in patients
with VAHS, whereas not observed in most cases of KD. The homeostasis of vascular endothelial function
by Ang-1 and Ang-2 is disrupted in MAS. Serum Ang-1 levels and the Ang-2/1 ratio might represent
promising indicators of disease activity for MAS.
 2016 Elsevier Ltd. All rights reserved.1. Introduction
Systemic juvenile idiopathic arthritis (s-JIA) is a unique subtype
of JIA, characterized by arthritis and other systemic features
including spiking fever, salmon colored skin rash, hep-
atosplenomegaly, generalized lymphadenopathy, and polyserositis
[1]. Recent studies have shown that s-JIA might be driven by innate
proinflammatory cytokines. In particular, interleukin (IL)-1, IL-6,
IL-18 play an important roles in the pathogenesis of s-JIA [2,3]. Fur-
thermore, biological therapies that block these cytokines have dra-
matic effects in patients with s-JIA [4,5]. These findings support the
hypothesis that s-JIA is an autoinflammatory condition.Macrophage activation syndrome (MAS) is a potentially fatal
condition of s-JIA, characterized by fever, cytopenias, hep-
atosplenomegaly, lymphadenopathy, liver dysfunction, coagulopa-
thy, and central nervous system dysfunction [6]. MAS is a
secondary form of hemophagocytic lymphohistiocytosis (HLH)
and massive hypercytokinemia induced by excess activation of
macrophages and proliferation of T lymphocytes is closely associ-
ated with the development of MAS [6].
Vascular endothelial cells activated by inflammatory cytokines
act as a procoagulant surface and contribute to intravascular coag-
ulation of s-JIA [2]. Angiopoietins (Ang)-1 and -2 are key regulators
of endothelial cell function [7,8]. In inflammatory conditions
including sepsis and hemolytic uremic syndrome, the Ang-2/1 ratio
increases because of decreased Ang-1, increased Ang-2 [9–12]. We
speculated that dysregulation of the Ang-2/1 is also present in s-
JIA, and that the homeostasis of vascular endothelial function by
Ang-1 and Ang-2 is disrupted in MAS.
To assess the role of Ang-1 and Ang-2 in endothelial damage in
the pathogenesis of s-JIA and MAS, we measured serum Ang-1 and
Ang-2 levels in patients with s-JIA. We compared them with the
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(VAHS), a secondary form of HLH as well as MAS and Kawasaki dis-
ease (KD), a popular pediatric vasculitis which complicates the vas-
cular endothelial damage. We determined the correlation between
the levels of serum Ang-1and Ang-2 levels, and the Ang-2/1 ratio
with measures of disease activity and severity in order to clarify
the clinical significance of these levels as indicators of disease
activity for MAS.2. Materials and methods
2.1. Patients and samples
Serum samples were obtained from 51 patients with s-JIA, 11
patients with polyarticular JIA (poly-JIA), 12 patients with Kawa-
saki disease (KD), and 15 age-matched healthy controls (HC) (mean
age s-JIA: 7.9 ± 5.4 years, mean age poly-JIA: 11.8 ± 5.0 years, mean
age KD: 1.5 ± 1.4 years, mean age HC: 9.3 ± 7.8 years). Plasma sam-
ples were obtained from 12 patients with virus associated
hemophagocytic syndrome (VAHS) (mean age VAHS:
5.0 ± 4.0 years). Eleven patients with s-JIA had MAS, and seven of
these had already developed MAS by the time they were referred
to us at the onset of s-JIA. Four patients with s-JIA developed
MAS during the active phase after beginning immunosuppressive
therapy with steroids and/or tocilizumab. Samples from these four
patients were obtained during the active and inactive phases of s-
JIA. The clinical characteristics of the patients with active s-JIA are
shown in Table 1. The clinical characteristics of the patients with
MAS are shown in Supplementary Table 1. Furthermore, samples
from 16 patients with s-JIA were obtained during the active and
inactive phases of s-JIA. The diagnoses of s-JIA and poly-JIA were
based on the criteria of the International League of Associations
for Rheumatology [13]. MAS was diagnosed based on the guideli-
nes proposed by Ravelli et al [14]. The criteria for the active phase
of s-JIA were defined as follows: active arthritis, fever, salmon col-
ored rash, hepatosplenomegaly, generalized lymphadenopathy,
polyserositis, increased erythrocyte sedimentation rate, and
increased serum C-reactive protein (CRP) level. The criteria for
the inactive phase of s-JIA on medication were as follows: the
absence of clinical symptoms observed in the active phase of s-
JIA, normal erythrocyte sedimentation rate, and normal serum
CRP level. The diagnosis of VAHS was made according to estab-
lished HLH diagnostic criteria [15]. The diagnosis of KD was based
on the classic clinical criteria [16].Table 1
Clinical characteristics of patients with active systemic juvenile idiopathic arthritis.
CRP, C-reactive protein; AST, aspartate aminotransferase; LDH, lactate dehydroge-
nase; FDP-DD, fibrin degradation product D-dimer; PSL, prednisolone; CyA,
cyclosporine; MTX, methotrexate; TCZ, tocilizumab.
Patients 44
Sex Male 20 female 24
Age (years) 8.4 ± 5.5
Disease duration (months) 11.2 ± 39.0
Laboratory findings
CRP (mg/dl) (n = 43) 10.1 ± 7.1
AST (IU/L) (n = 48) 47.5 ± 33.1
LDH (IU/L) (n = 48) 367.1 ± 150.2
Ferritin (ng/ml) (n = 48) 1669.4 ± 2926.7
FDP-DD (n = 34) 6.1 ± 7.0
Treatment
PSL (mg/kg/day) (n = 13) 0.77 ± 0.55
CyA (mg/kg/day) (n = 5) 2.7 ± 1.6
MTX (mg/m2/week) (n = 1) 10
TCZ (mg/kg/2 weeks) (n = 5) 8Sera and plasma were separated from the cells, divided into ali-
quots, frozen, and stored at 80 C until use. This study was
approved by the Institutional Review Board at Kanazawa Univer-
sity, and all specimens were used only after informed consent
was obtained according to the Declaration of Helsinki.2.2. Quantification of serum cytokines
Levels of Ang-1 and Ang-2 were evaluated using enzyme-linked
immunosorbent assay (ELISA), according to the manufacturer’s
instructions (RayBio Human Angiopoietin-1, -2 ELISA kit, RayBio-
tech, Norcross, GA, USA). The levels of Ang-1 and Ang-2 could be
measured equally well in plasma and serum samples.2.3. Statistical analysis
Within-group comparisons were analyzed using the Mann–
Whitney test or paired t-test. Correlations were analyzed using
the Spearman rank correlation coefficient. Analyzed measures with
p values <0.05 were considered to be statistically significant.3. Results
3.1. Disruption of vascular endothelial homeostasis by Ang-1 and Ang-
2 in s-JIA and MAS
The serum Ang-1 and Ang-2 levels were determined in patients
with s-JIA, and compared with the levels in patients with poly-JIA,
VAHS, KD and in HC. As shown in Fig. 1A, during the MAS phase in
patients with s-JIA, the serum Ang-1 levels were significantly
decreased (41,583 ± 27,773 pg/ml) compared with those during
the active (100,866 ± 42,949 pg/ml, p = 0.0001) and inactive phases
(120,553 ± 33,076 pg/ml, p < 0.0001) in patients with s-JIA, and
compared with those in patients with poly-JIA
(101,850 ± 25,951 pg/ml, p < 0.01), in KD (114,517 ± 23,080 pg/ml,
p < 0.001) and in HC (100,740 ± 31,718 pg/ml, p < 0.001). Serum
Ang-1 levels in patients with VAHS were also significantly
decreased (41,583 ± 27,773 pg/ml) compared with those during
the active and inactive phases in patients with s-JIA, and compared
with those in patients with poly-JIA, in KD and in HC
(100,740 ± 31,718 pg/ml, p < 0.001). As shown in Fig. 1B, during
the MAS phase in patients with s-JIA, serum Ang-2 levels were sig-
nificantly elevated (8750 ± 7488 pg/ml) compared with those dur-
ing the active (5514 ± 5392 pg/ml, p < 0.05) and inactive phases
(2836 ± 1341 pg/ml, p < 0.01) in patients with s-JIA, and compared
with those in patients with poly-JIA (2631 ± 1554 pg/ml, p < 0.05),
in VAHS (5225 ± 6784 pg/ml, p < 0.05), in KD (4191 ± 3704 pg/ml,
p < 0.01) and in HC (2317 ± 1035 pg/ml, p < 0.001). As shown in
Fig. 1C, during the MAS phase in patients with s-JIA, the Ang-2/1
ratio was significantly elevated (0.272 ± 0.254 pg/ml) compared
with that during the active (0.066 ± 0.071 pg/ml, p < 0.001) and
inactive phases (0.026 ± 0.012 pg/ml, p < 0.0001) in patients with
s-JIA, and compared with those in patients with poly-JIA
(0.028 ± 0.019 pg/ml, p < 0.001), in KD (0.036 ± 0.028 pg/ml,
p < 0.0001) and in HC (0.023 ± 0.007 pg/ml, p < 0.0001). Further-
more, as shown in Fig. 1C, during the active phase, the Ang-2/1
ratio was significantly elevated compared with that during the
inactive phase in patients with s-JIA (p < 0.01), and compared with
that in patients with poly-JIA (p < 0.05) and in HC (p < 0.01)
(Fig. 1C). However, the Ang-2/1 ratio during the active phase of
s-JIA were significantly decreased compared with those in patients
with VAHS (0.165 ± 0.196 pg/ml, p < 0.05).
Fig. 1. Serum angiopoietin (Ang)-1 (A) and -2 (B) levels and the Ang-2/1 ratio (C) in
patients with systemic juvenile idiopathic arthritis. Bars represent median values.
Ang-1, angiopoietin-1; Ang-2, angiopoietin-2; poly-JIA, polyarticular juvenile
idiopathic arthritis; VAHS, virus associated hemophagocytic syndrome; KD,
Kawasaki disease; HC, healthy controls. Statistically significant differences between
each patient group are shown as, ⁄P < 0.05, ⁄⁄P < 0.01, ⁄⁄⁄P < 0.001, and ⁄⁄⁄⁄P < 0.001.
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ratio in four patients with MAS
To investigate the relevance of Ang-1 and Ang-2 in the patho-
genesis of MAS, serum Ang-1 and Ang-2 levels were serially mon-
itored in four cases of MAS (Fig. 2A–D). The serum Ang-1 levels
profoundly and rapidly decreased as MAS developed. However,
the Ang-2/1 ratio profoundly and rapidly increased as MAS devel-
oped. The Ang-2/1 ratio subsequently decreased after such mani-
festations disappeared with immunosuppressive therapy. As
shown in Fig. 2A and D, in cases of uncontrolled disease activity,
serum Ang-1 levels were decreased and the Ang-2/1 ratio was
elevated.
3.3. Correlation between serum Ang-1 and Ang-2 levels and Ang-2/1
ratio and measures of disease activity in patients with s-JIA and MAS
Because serum CRP, aspartate aminotransferase (AST), lactate
dehydrogenase (LDH), and ferritin levels are clinically used as indi-
cators of disease activity in s-JIA, these levels were compared with
the serum Ang-1 and Ang-2 levels and the Ang-2/1 ratio. Serum
Ang-1 levels negatively correlated with AST, LDH, and ferritin
(Fig. 3A–C). Serum Ang-2 levels positively correlated with AST
and LDH (Fig. 3D and E). The Ang-2/1 ratio positively correlated
with AST, LDH, and ferritin (Fig. 4A–C). Furthermore, levels of the
plasma fibrin degradation product D-dimer (FDP-DD) are clinically
used as indicators of coagulopathy. Therefore, FDP-DD concentra-
tions were compared with serum Ang-1 and Ang-2 levels and the
Ang-2/1 ratio. The Ang-2/1 ratio positively correlated with FDP-
DD concentrations (Fig. 4D).4. Discussion
Ang-1 and Ang-2 competitively bind to the endothelial Tie-2
receptor [7,8]. Ang-1 is constitutively produced by pericytes,
smooth muscle cells and fibroblast. Ang-2 is produced by endothe-
lial cells. In healthy individuals, Ang-2 expression is almost absent
in the resting vasculature. Serum concentrations of Ang-1 exceed
those of Ang-2 and Ang2/1 ratio is low. Ang-1 binds to the Tie-2
receptor and control vascular quiescence through the negative reg-
ulation of proinflammatory pathways [7,8]. In inflammatory condi-
tions, Ang-2 expression is dramatically induced by various stresses.
Ang-2 is released from endothelial cells and competes with Ang-1
for binding to the Tie-2 receptor. Consequently, Ang-2 triggers
proinflammatory and prothrombotic pathways by activating
endothelial cells.
Various stresses including hypoxia, inflammation, and high glu-
cose concentrations induce Ang2/1 dysregulation [7,8]. Cytokines
and growth factors including tumor necrosis factor (TNF)-a, vascu-
lar endothelial growth factor, and fibroblast growth factor promote
destabilized angiogenesis by modulating angiopoietin expression
[7,8]. Among the cytokines closely related to the pathogenesis of
s-JIA, previous studies have shown that IL-1b downregulates
Ang-1 expression [17]. Furthermore, IL-6 inhibits Ang-1 signaling
by downregulating Ang-1 expression and upregulating Ang-2
expression [18,19].
In this study, we demonstrated that the Ang-2/1 ratio, which
reflects a relative excess of Ang-2, was significantly elevated in
the active phase of s-JIA. Furthermore, serum Ang-1 levels were
significantly decreased in MAS, whereas the serum Ang-2 levels
and the Ang-2/1 ratio were significantly elevated in MAS. These
findings are consistent with the known biological roles of Ang-1
Fig. 2. Changes in serum angiopoietin (Ang)-1 levels and Ang-2/1 ratio in 4 patients with macrophage activation syndrome. Changes in serum levels of Ang-1 (solid lines) and
the Ang-2/1 ratio (dotted lines) are shown in the middle panels, and the serum LDH (solid lines) levels are shown in the lower panels. Details of the therapeutic interventions
are shown in the upper panels. PSL, prednisolone; mPSL, methylprednisolone; CyA, cyclosporine; DEX-P, dexamethasone palmitate; MAS, macrophage activation syndrome.
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in the pathogenesis of s-JIA and MAS. In agreement with these
findings, endothelial cell dysfunction by Ang-2/1 dysregulation is
present in children with s-JIA and represents the clinical manifes-
tation of endothelial cell dysfunction. In the pathology of s-JIA,
proinflammatory cytokines, such as IL-1b and IL-6, induce Ang2/1
dysregulation through downregulation of Ang-1 expression and
upregulation of Ang-2 expression. Furthermore, the homeostasis
of endothelial function by Ang-1 and Ang-2 is disrupted as MAS
develops, inducing vascular endothelial cell damage and coagu-
lopathy. Interestingly, Ang-2/1 dysregulation was also observed
in patients with VAHS, a secondary form of HLH as well as MAS.
In contrast, Ang-2/1 dysregulation was not observed in most cases
of KD. From these findings, Ang-2/1 dysregulation is characteristic
to the diseases with progressive endothelial dysfunction such as
MAS and HLH.
In this study, the Ang-2/1 ratio profoundly and rapidly
increased as MAS developed. Furthermore, the Ang-2/1 ratio
decreased after such manifestations disappeared with corticos-
teroid and cyclosporine therapy. As shown in Fig. 1A and D, serum
Ang-1 levels were decreased and the Ang-2/1 ratio was elevated in
cases of uncontrolled disease activity. From these findings, the
Ang-2/1 ratio may represent a promising indicator of disease activ-
ity for MAS.In addition to the role of Ang-2/1 in the homeostasis of
endothelial function, several lines of evidence have suggested that
Ang-1 and Ang-2 play roles in the exacerbation of synovitis in
patients with rheumatoid arthritis (RA) [18,20,21]. Ang-1, Ang-2,
and Tie2, are expressed in RA synovial tissue [20,21]. In the syn-
ovial tissue of RA patients, Tie2 activation has been shown to be
predominantly localized to macrophages [18]. Ang-1/2 has been
shown to stimulate the activation of intracellular signaling path-
ways, and cooperate with TNF to induce macrophage IL-6 and
macrophage inflammatory protein 1a production [21]. These find-
ings indicate that the synovial macrophage is a primary target of
Ang-signaling, promoting the proinflammatory activation of
human macrophages. In animal models of RA, neutralization of
Ang-2 was shown to significantly decrease disease severity, syn-
ovial inflammation, neo-vascularization, and joint destruction
[21]. From these findings, Ang-1 and Ang-2 may play important
roles in the development of arthritis in s-JIA and RA. Furthermore,
direct targeting of Ang-2 may provide therapeutic benefit in the
treatment of s-JIA-associated MAS.
The limitation of the present study was the small number of
patients with s-JIA. Further larger studies may help to define the
true diagnostic value of Ang -1 and Ang-2. However, despite this
limitation, our results suggest that Ang-1 and Ang-2 play impor-
tant roles in the complex network involved in the inflammation
Fig. 3. Correlations between serum angiopoietin (Ang)-1 and Ang-2 levels and measures of disease activity. (A, Ang-1 and AST; B, Ang-1 and LDH; C, Ang-1 and ferritin; D,
Ang-2 and AST; E, Ang-2 and LDH). AST, aspartate aminotransferase; LDH, lactate dehydrogenase.
Fig. 4. Correlations between angiopoietin 2/1 ratio and measures of disease activity. (A, AST; B, LDH; C, ferritin; D, FDP-DD). AST, aspartate aminotransferase; LDH, lactate
dehydrogenase; FDP-DD, fibrin degradation product D-dimer.
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and Ang-2 is disrupted in MAS. The Ang-2/1 ratio may represent a
promising indicator of disease activity for MAS.Funding source
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